Brendan Eckelman, Ph.D.

Founder, Chief Operating Officer

Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporation strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine.